Clinical characteristics and prognostic factors in patients with malignant melanoma: A Chinese prospective cohort study

Table 1 Clinical characteristics of patients with malignant melanoma

Variable	n (%)	Variable	n (%)	Variable	n (%)	Variable	n (%)
Age (years)		Tumor stage		Types of health insurance		Use of interferon
≤ 50	206 (27.14)	Ⅰ-Ⅱ	172 (22.66)	Resident health insurance	410 (54.02)	No	662 (87.22)
51-70	404 (53.23)	Ⅲ	166 (21.87)	Employee health insurance	206 (27.14)	Yes	96 (12.65)
≥ 71	149 (19.63)	Ⅳ	250 (32.94)	Self-funded and others	143 (18.84)	Use of anti-tumor angiogenic drugs
Sex		Radiotherapy		Clinical classification		No	724 (95.39)
Female	373 (49.14)	No	643 (84.72)	Cutaneous	138 (18.18)	Yes	34 (4.48)
Male	386 (50.86)	Yes	116 (15.28)	Acral	361 (47.56)	Operation
Marriage		Chemotherapy		Mucosal	137 (18.05)	No	228 (30.04)
Married	697 (91.83)	No	481 (63.37)	Ocular	33 (4.35)	Yes	531 (69.96)
Others	62 (8.17)	Yes	278 (36.63)	Types of undetermined origin	90 (11.86)	Platelets*
Underlying diseases1		Immunotherapy		Combined with other tumors		Normal	645 (84.98)
No	625 (82.35)	No	634 (83.53)	No	736 (96.97)	Low	75 (9.88)
Yes	134 (17.65)	Yes	124 (16.34)	Yes	23 (3.03)	High	28 (3.69)
Ethnicity		Targeted therapy		Use of interleukins		Lactate dehydrogenase2
Han	739 (97.36)	No	728 (95.92)	No	711 (93.68)	Normal	493 (64.95)
Others	20 (2.64)	Yes	30 (3.95)	Yes	47 (6.19)	Low	6 (0.79)
						High	134 (17.65)

¹Normal platelet range: 125-350 × 10⁹/L, low is below 125 × 10⁹/L, high is above 350 × 10⁹/L.

²Normal lactate dehydrogenase range: 120-250 U/L; low is less than 120 U/L; high is greater than 250 U/L.

One patient lacked data on the use of interferon therapy, antiangiogenic drugs, interleukin therapy, immunotherapy and targeted therapy.